325 related articles for article (PubMed ID: 12423443)
1. Sensitization to saw palmetto and minoxidil in separate topical extemporaneous treatments for androgenetic alopecia.
Sinclair RD; Mallari RS; Tate B
Australas J Dermatol; 2002 Nov; 43(4):311-2. PubMed ID: 12423443
[TBL] [Abstract][Full Text] [Related]
2. Positive lymphocyte transformation test in a patient with allergic contact dermatitis of the scalp after short-term use of topical minoxidil solution.
Hagemann T; Schlütter-Böhmer B; Allam JP; Bieber T; Novak N
Contact Dermatitis; 2005 Jul; 53(1):53-5. PubMed ID: 15982234
[TBL] [Abstract][Full Text] [Related]
3. Allergic contact dermatitis to topical minoxidil solution: etiology and treatment.
Friedman ES; Friedman PM; Cohen DE; Washenik K
J Am Acad Dermatol; 2002 Feb; 46(2):309-12. PubMed ID: 11807448
[TBL] [Abstract][Full Text] [Related]
4. Pustular dermatosis of the scalp due to topical minoxidil 5.
El Anzi O; Hassam B
Pan Afr Med J; 2018; 30():83. PubMed ID: 30344867
[No Abstract] [Full Text] [Related]
5. Alternative formulation for patients with contact reactions to topical 2% and 5% minoxidil vehicle ingredients.
Scheman AJ; West DP; Hordinksy MK; Osburn AH; West LE
Contact Dermatitis; 2000 Apr; 42(4):241. PubMed ID: 10750861
[No Abstract] [Full Text] [Related]
6. Use of topical minoxidil therapy for androgenetic alopecia in women.
Jacobs JP; Szpunar CA; Warner ML
Int J Dermatol; 1993 Oct; 32(10):758-62. PubMed ID: 8225725
[TBL] [Abstract][Full Text] [Related]
7. Allergic contact dermatitis from minoxidil.
Ebner H; Müller E
Contact Dermatitis; 1995 May; 32(5):316-7. PubMed ID: 7634798
[No Abstract] [Full Text] [Related]
8. Treatment of male androgenetic alopecia with topical products containing Serenoa repens extract.
Wessagowit V; Tangjaturonrusamee C; Kootiratrakarn T; Bunnag T; Pimonrat T; Muangdang N; Pichai P
Australas J Dermatol; 2016 Aug; 57(3):e76-82. PubMed ID: 26010505
[TBL] [Abstract][Full Text] [Related]
9. Pigmented contact dermatitis from topical minoxidil 5%.
Trattner A; David M
Contact Dermatitis; 2002 Apr; 46(4):246. PubMed ID: 12081710
[No Abstract] [Full Text] [Related]
10. Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women.
Blume-Peytavi U; Kunte C; Krisp A; Garcia Bartels N; Ellwanger U; Hoffmann R
J Dtsch Dermatol Ges; 2007 May; 5(5):391-5. PubMed ID: 17451383
[TBL] [Abstract][Full Text] [Related]
11. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
Olsen EA; Dunlap FE; Funicella T; Koperski JA; Swinehart JM; Tschen EH; Trancik RJ
J Am Acad Dermatol; 2002 Sep; 47(3):377-85. PubMed ID: 12196747
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.
Olsen EA; Whiting D; Bergfeld W; Miller J; Hordinsky M; Wanser R; Zhang P; Kohut B
J Am Acad Dermatol; 2007 Nov; 57(5):767-74. PubMed ID: 17761356
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.
Lucky AW; Piacquadio DJ; Ditre CM; Dunlap F; Kantor I; Pandya AG; Savin RC; Tharp MD
J Am Acad Dermatol; 2004 Apr; 50(4):541-53. PubMed ID: 15034503
[TBL] [Abstract][Full Text] [Related]
14. A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia.
Suchonwanit P; Rojhirunsakool S; Khunkhet S
Lasers Med Sci; 2019 Dec; 34(9):1857-1864. PubMed ID: 30982177
[TBL] [Abstract][Full Text] [Related]
15. An analysis of gene expression data involving examination of signaling pathways activation reveals new insights into the mechanism of action of minoxidil topical foam in men with androgenetic alopecia.
Stamatas GN; Wu J; Pappas A; Mirmirani P; McCormick TS; Cooper KD; Consolo M; Schastnaya J; Ozerov IV; Aliper A; Zhavoronkov A
Cell Cycle; 2017; 16(17):1578-1584. PubMed ID: 28594262
[TBL] [Abstract][Full Text] [Related]
16. Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution.
DeVillez RL; Jacobs JP; Szpunar CA; Warner ML
Arch Dermatol; 1994 Mar; 130(3):303-7. PubMed ID: 8129407
[TBL] [Abstract][Full Text] [Related]
17. The use of minoxidil in the treatment of male and female androgenetic alopecia: a story of more than 30 years.
Barbareschi M
G Ital Dermatol Venereol; 2018 Feb; 153(1):102-106. PubMed ID: 29319278
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic use of topical minoxidil.
DeVillez RL
Dermatol Clin; 1990 Apr; 8(2):367-75. PubMed ID: 2191807
[TBL] [Abstract][Full Text] [Related]
19. Androgenetic alopecia: an evidence-based treatment update.
Varothai S; Bergfeld WF
Am J Clin Dermatol; 2014 Jul; 15(3):217-30. PubMed ID: 24848508
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.
Tsuboi R; Arano O; Nishikawa T; Yamada H; Katsuoka K
J Dermatol; 2009 Aug; 36(8):437-46. PubMed ID: 19691748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
